Tariquidar (XR9576)

Catalog No.S8028

For research use only.

Tariquidar (XR9576) is a potent and selective noncompetitive inhibitor of P-glycoprotein with Kd of 5.1 nM in CHrB30 cell line, reverses drug resistance in MDR cell Lines. Phase 3.

Tariquidar (XR9576) Chemical Structure

CAS No. 206873-63-4

Selleck's Tariquidar (XR9576) has been cited by 36 publications

Purity & Quality Control

Choose Selective P-gp Inhibitors

Other P-gp Products

Biological Activity

Description Tariquidar (XR9576) is a potent and selective noncompetitive inhibitor of P-glycoprotein with Kd of 5.1 nM in CHrB30 cell line, reverses drug resistance in MDR cell Lines. Phase 3.
Targets
P-gp [1]
(CHrB30 cells)
5.1 nM(Kd)
In vitro

Tariquidar displays high-affinity binding to P-gp with Bmax of 275 pmol/mg. Tariquidar shows non-competitive interaction with the P-gp substrates vinblastine and paclitaxel. Tariquidar increases the steady-state accumulation of these cytotoxics in CHrB30 cells to levels observed in non-P-gp-expressing AuxB1 cells with EC50 of 487 nM. Tariquidar is able to inhibit the vanadate-sensitive ATPase activity of P-gp by 60-70%, with potent IC50 values of 43 nM. [1] Tariquidar may inhibit other resistance mechanisms at higher concentrations. 1 μM Tariquidar abrogates ABCG2 (BCRP)-mediated resistance to camptothecins in vitro. [2] Tariquidar potentiates the cyto-toxicity of several drugs including doxorubicin, paclitaxel, etoposide, and vincristine; complete reversal of resistance is achieved in the presence of 25- 80 nM Tariquidar. In MC26, a murine colon carcinoma cell line with intrinsic chemoresistance, the doxorubicin IC50 is fivefold lower in the presence of 0.1 μM Tariquidar (36 vs 7 nM). In murine mammary carcinoma, human small-cell lung carcinoma and human ovarian carcinoma cell lines with acquired chemotherapeutic resistance (EMT6/AR1.0, H69/LX4 and 2780 AD), the in vitro doxorubicin IC50 is 22-150-fold lower in the presence of 0.1 μM Tariquidar. P-gp inhibition persists for 23 h after removal of Tariquidar from the culture system. [3] Tariquidar restored the cyto-toxicity of doxorubicin and vinblastine in the National Cancer Institute (NCI)/ADRRES multicellular tumor spheroid model derived from the MCF7WT breast cancer cell line. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KB-3-1 M2fUOWZ2dmO2aX;uJIF{e2G7 NFXzOmwyODByIH7N NYnPUVM4PzJiaILz MoniVI91\W62aXH0bY9vKG:oII\pcoNzcXO2aX7lMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2IuOy1zIHPlcIx{KGG|c3Xzd4VlKGG|II\pcoNzcXO2aX7lJGlEPTBiYYSgNVAxOCCwTTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IDjSeoIhRSByLke4JEswNSByLkK3JI5OMSxiSVO1NF0xNjByMESx{txO MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzVyNE[2PUc,Ojd3MES2Olk9N2F-
KBV1 NGfyNWJHfW6ldHnvckBie3OjeR?= Mn75NVAxOCCwTR?= M17tTlczKGi{cx?= NIDQUYNKdmirYnn0bY9vKG:oIHj1cYFvKEGEQ1KxJIV5eHKnc4Pl[EBqdiCNQm[xJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjD2bY5kemm|dHnu[U1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCkeTDt[YF{fXKrbnegeolv[3Krc4TpcoUhUUN3MDDheEAyODByIH7NJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmgLHJ3[iB;IEK3O{43QCBtLz2gOVYvPjFibl2pMEBKSzVyPUCuNFAxPjcQvF2= MnvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3MES2OlkoRjJ5NUC0OlY6RC:jPh?=
HEK293 MlWzSpVv[3Srb36gZZN{[Xl? MnjpNVAxOCCwTR?= MofMO|IhcHK| NUnBXoh6WG:2ZX70bYF1cW:wIH;mJIRwgG:{dXLpZ4lvNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGSxeH;yeYJq[2mwIFnDOVAh[XRiMUCwNEBvVSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSBqUo\iJF0hPS5{ODCrM{0hOC55NDDuUUktKEmFNUC9NE4xODR7Nd88US=> NFzG[YQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{WwOFY3QSd-Mke1NFQ3Pjl:L3G+
OVCAR8 M2rlfGZ2dmO2aX;uJIF{e2G7 NXHqNmhOOTByMDDuUS=> NVHOfIczPzJiaILz NXvRZZpFWG:2ZX70bYF1cW:wIH;mJJZqdmO{aYP0bY5mNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWK4JINmdGy|IHHzd4V{e2WmIHHzJJZqdmO{aYP0bY5mKEmFNUCgZZQhOTByMDDuUUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5JEhTfmJiPTC4MlU{KCtxLTCxMlk2KG6PKTygTWM2OD1yLkCwOVE5|ryP MkXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3MES2OlkoRjJ5NUC0OlY6RC:jPh?=
KB-3-1 MX7GeY5kfGmxbjDhd5NigQ>? M2WxR|ExODBibl2= MVPQc5RmdnSrYYTpc44hd2ZiY3;sZ4hq[2mwZT3pcoR2[2WmIHP5eI91d3irY3n0fUBi\2GrboP0JIh2dWGwIFvCMVMuOSClZXzsd{Bie3Onc4Pl[EBieyClb3zjbIlkcW6nIFnDOVAh[XRiMUCwNEBvVSCkeTDNWHQh[XO|YYmgLHJ3[iB;IEiuPFEhMy9vIEOuPFAhdk1rLDDJR|UxRTBwMEC4OFHPxE1? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzVyNE[2PUc,Ojd3MES2Olk9N2F-
KBV1 M3j1d2Z2dmO2aX;uJIF{e2G7 M1X5ZlExODBibl2= NV\F[o44PzJiaILz NH3C[3NKdmirYnn0bY9vKG:oIHj1cYFvKEGEQ1KxJIV5eHKnc4Pl[EBqdiCNQm[xJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDjc4xkcGmlaX7lMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzDjc4xkcGmlaX7lJGlEPTBiYYSgNVAxOCCwTTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IDjSeoIhRSB2OEeuOVchMy9vIEOwMlU1KG6PKTygTWM2OD1yLkCwPVA2|ryP MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzVyNE[2PUc,Ojd3MES2Olk9N2F-
MDCK MYHGeY5kfGmxbjDhd5NigQ>? MkTiN|AhdWmwcx?= M4HmXmFkfGm4aYT5JIF1KEKFUmCgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hVUSFSzDj[YxteyC3c3nu[{BzcG:mYX3pcoUhOTJ|IHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IEOwJI1qdnNicILpc5IhfG9ic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMh[nliZnz1c5JwdWW2cnnjJIFv[Wy7c3nzMEBGSzVyPUCuNFHPxE1? M1rRWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{e0PFczLz5{M{O3OFg4OjxxYU6=
NCI-ADR-RES NXO4XXE1TnWwY4Tpc44h[XO|YYm= NHfxW|AyODByIH7N NIDObIU4OiCqcoO= NX\DW|J6UW6qaXLpeIlwdiCxZjDoeY1idiCDQlPCNUBmgHC{ZYPz[YQhcW5iTlPJMWFFWi2URWOgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oII\pcoNzcXO2aX7lMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzD2bY5kemm|dHnu[UBKSzVyIHH0JFExODBibl2gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTCoVpZjKD1iM{exOE45OCBtLz2gN|g{NjV6IH7NLUwhUUN3ME2wMlAyQDVzzszN NW\We3FORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1NFQ3PjlpPkK3OVA1PjZ7PD;hQi=>
OVCAR8 M2rDWWZ2dmO2aX;uJIF{e2G7 M{Pyb|ExODBibl2= NHf1T5g4OiCqcoO= NX\3cIdsWG:2ZX70bYF1cW:wIH;mJINwdGOqaXPpcoUucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBQXkODUkigZ4VtdHNiYYPz[ZN{\WRiYYOgZ49t[2irY3nu[UBKSzVyIHH0JFExODBibl2gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTCoVpZjKD1iMkeuNlYhMy9vIEmuPVYhdk1rLDDJR|UxRTBwMEKzO|PPxE1? MlnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3MES2OlkoRjJ5NUC0OlY6RC:jPh?=
HEK293 MVTGeY5kfGmxbjDhd5NigQ>? Mm\ENVAxOCCwTR?= NE\iems4OiCqcoO= M1zKTGlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFQkGgeJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KHCxdHXueIlifGmxbjDv[kBld3ixcoXibYNqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDifUBu\WG|dYLpcoch\G:6b4L1ZolkcW5iSVO1NEBifCBzMECwJI5OKGGodHXyJFczKGi{czDifUBES0t6IHHzd4F6KCiUdnKgQUA2ODRwNkWgL{8uKDR2Lkm0JI5OMSxiSVO1NF0xNjB{NEe3{txO Ml7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3MES2OlkoRjJ5NUC0OlY6RC:jPh?=
NCI-ADR-RES M2fXZ2Z2dmO2aX;uJIF{e2G7 M4O0flExODBibl2= MYO3NkBpenN? MUjJcohq[mm2aX;uJI9nKGi3bXHuJGFDS0JzIHX4dJJme3OnZDDpckBPS0lvQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCyb4TlcpRq[XSrb36gc4Yh[2:uY3jpZ4lv\S2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDifUBu\WG|dYLpcoch[2:uY3jpZ4lv\SCLQ{WwJIF1KDFyMECgcm0h[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUApWn[kIE2gNVYxPy53MDCrM{0hPDl5LkSyJI5OMSxiSVO1NF0xNjB{NEm3{txO MlfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3MES2OlkoRjJ5NUC0OlY6RC:jPh?=
CCRF-CEM/VCR1000 MlzrSpVv[3Srb36gZZN{[Xl? NVK0c5BZOjRyIIPlZ5M> M1K2UGlvcGmkaYTpc44hd2ZiUD3ncJlkd3C{b4TlbY4udWWmaXH0[YQh\GG3bn;yeYJq[2mwIHXm[ox2gCCocn;tJIh2dWGwIFPDVmYuS0WPL2\DVlExODBiY3XscJMh[W[2ZYKgNlQxKHOnY4OgZpkhTkGFUzDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:OC5yM{OxNe69VQ>? Mn7kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2NUK0NVIoRjJ{NEWyOFEzRC:jPh?=
MDCK NIjBUYxHfW6ldHnvckBie3OjeR?= NVvrV|FDOzBibXnudy=> M3HWO2FkfGm4aYT5JIF1KE2GUkGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hVUSFSzDj[YxteyC3c3nu[{Bk[WylZXnuJGFOKGG|IIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDNyIH3pcpMheHKrb4KgeI8he3Wkc4TyZZRmKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkh\my3b4LvcYV1emmlIHHuZYx6e2m|LDDFR|UxRTBwMES0{txO MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5NEi3Nkc,OjN|N{S4O|I9N2F-
MDCK M2q4UGZ2dmO2aX;uJIF{e2G7 MYezNEBucW6| NI\rPXNKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF3ER2sh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIHPhcINmcW5vQV2geJJidnOyb4L0JIFnfGW{IEOwJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG|c3H5MEBGSzVyPUCuNFQ1|ryP NXLOdYxzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc6QTlpPkK0OlA4QTl7PD;hQi=>
EMT6/AR1.0 NXjBcnlUTnWwY4Tpc44h[XO|YYm= NIfZUnYyKGi{ NVe1UJI5UW6qaXLpeIlwdiCxZjDtc5V{\SCSZ4CgbY4hTU2WNj;BVlEvOCClZXzsd{Bi\nSncjCxJIhzKGK7IHTheY5wenWkaXPpckBi[2O3bYXsZZRqd25iYYPzZZktKEmFNUC9NE4xPjUQvF2= MlewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyOEOwN|QoRjF6MEizNFM1RC:jPh?=
EMT6/AR1.0 NXn6eWpkTnWwY4Tpc44h[XO|YYm= MlLYNUBpeg>? NF;pVpBKdmirYnn0bY9vKG:oIH3veZNmKFCpcDDpckBGVVR4L1HSNU4xKGOnbHzzJIFnfGW{IEGgbJIh[nliZHH1co9zfWKrY3nuJIFk[3WvdXzheIlwdiCjc4PhfUwhUUN3ME2wMlA3PDV5zszN M{DuUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEizNFM1Lz5zOEC4N|A{PDxxYU6=
CEM/VLB500 NUfKdoVzTnWwY4Tpc44h[XO|YYm= MmiyN{Bl[Xm| MmPJVoV3\XK|YXygc4YhWC2pcD3t[YRq[XSnZDDteYx1cWS{dXegdoV{cXO2YX7j[UB1dyC4aX7icIF{fGmwZTDpckBpfW2jbjDDSW0wXkyENUCwJINmdGy|IHHmeIVzKDNiZHH5d{BjgSC{ZYPhfpVzcW5iYYPzZZktKEWFNUC9NE4xPjkQvF2= NFvCVng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O5PVk6OCd-MUezPVk6QTB:L3G+
KBV1 NFi2UnRHfW6ldHnvckBie3OjeR?= NGjXeFYyODByIH7N NVvjVYRCPzJiaILz NEjmR4pKdmirYnn0bY9vKG:oIHj1cYFvKEGEQ1KxJIV5eHKnc4Pl[EBqdiCNQm[xJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDkc5hwenWkaXPpck1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCkeTDt[YF{fXKrbneg[I95d3K3YnnjbY4hUUN3MDDheEAyODByIH7NJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmgLHJ3[iB;IEWuNFchMy9vIECuNVkhfU1rLDDJR|UxRTBwMEhOwG0> M2Wz[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUC0OlY6Lz5{N{WwOFY3QTxxYU6=
A2780 NGDHUGhHfW6ldHnvckBie3OjeR?= M{LXdWlvcGmkaYTpc44hd2ZiUD3ndEBqdiCqdX3hckBi\HKrYX35Z4lvNXKnc3nzeIFvfCCDMke4NEBk\WyuczDifUBJd2WlaIP0JFM{OzR{IHHzd4F6NCCLQ{WwQVAvODd{NEVOwG0> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ5OES5OUc,OTh4N{i0PVU9N2F-
A2780/ADR NGLGVoZHfW6ldHnvckBie3OjeR?= Mlm5TY5pcWKrdHnvckBw\iCSLXfsfYNweHKxdHXpck1u\WSrYYTl[EBufWy2aXTyeYchemW|aYP0ZY5k\SCrbjDh[JJq[W27Y3nuMZJme2m|dHHueEBpfW2jbjDBNlc5OC:DRGKgZ4VtdHNiYomgZ4Ft[2WrbjDBUUBie3OjeTygTWM2OD1yLkC3PO69VQ>? M3u2SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkWwPFM1Lz5zOUK1NFg{PDxxYU6=
A2780adr MVXGeY5kfGmxbjDhd5NigQ>? MWLJcohq[mm2aX;uJI9nKFBvZ4Cg[ZhxemW|c3XkJIlvKEF{N{iwZYRzKGOnbHzzJIJ6KGOjbHPlbY4hSU1iYXPjeY12dGG2aX;uJIF{e2G7LDDJR|UxRTBwMElOwG0> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN3NEiwNEc,OjF|NUS4NFA9N2F-
OVCAR8 NH;Meo9HfW6ldHnvckBie3OjeR?= NUDyRnhWOTByMDDuUS=> M3zkflczKGi{cx?= MkXnVI91\W62aXH0bY9vKG:oIHTvfI9zfWKrY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHTvfI9zfWKrY3nuJGlEPTBiYYSgNVAxOCCwTTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IDjSeoIhRSByLkGyJEswNSByLkCzJJVOMSxiSVO1NF0xNjB6zszN M4fLbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUC0OlY6Lz5{N{WwOFY3QTxxYU6=
KB-3-1 M4rufGZ2dmO2aX;uJIF{e2G7 NHr3O|AyODByIH7N NFfm[pY4OiCqcoO= NIS0cHNRd3SnboTpZZRqd25ib3[g[I95d3K3YnnjbY4ucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSi1|LUGgZ4VtdHNiYYPz[ZN{\WRiYYOg[I95d3K3YnnjbY4hUUN3MDDheEAyODByIH7NJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmgLHJ3[iB;IECuNVUhMy9vIECuNFQhfU1rLDDJR|UxRTBwMUJOwG0> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzVyNE[2PUc,Ojd3MES2Olk9N2F-
A2780 NGHUR5pHfW6ldHnvckBie3OjeR?= M4TWbVMxKG2rboO= NIjKbHdKdmirYnn0bY9vKG:oIHj1cYFvKFCpcDDpckBCOjd6MDDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KEixZXPod5QhOzN|NEKgZZN{[XluIFnDOVA:OC5zMkW4Pe69VQ>? NYC3eppURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwPFMxOzRpPkG4NFg{ODN2PD;hQi=>
MDCK MVzGeY5kfGmxbjDhd5NigQ>? NWXWN2pxUW6qaXLpeIlwdiCxZjDNSHIyKGW6cILld5Nm\CCrbjDNSGNMKGOnbHzzJJV{cW6pIILoc4RidWmwZTCxNlMhe3SjaX7pcoch[nliZnzve{BkgXSxbXX0dpktKEmFNUC9NE4zOc7:TR?= M4LUclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{W0PFAxLz5{MUO1OFgxODxxYU6=
KBV1 MXjGeY5kfGmxbjDhd5NigQ>? MYPJcohq[mm2aX;uJI9nKEGEQ1KxJIlvKGi3bXHuJGtDXjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk[WylZXnuMWFOKGWoZnz1fEwhUUN3ME2wMlIz|ryP M2PxclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{e0NFM5Lz5{Nke3OFA{QDxxYU6=
KBv1 MXjGeY5kfGmxbjDhd5NigQ>? NGi2N2hKdmirYnn0bY9vKG:oIFHCR2IyKG:4ZYLlfJBz\XO|ZXSgbY4hcHWvYX6gT2J3OSClZXzsd{BjgSCobH;3JIN6fG:vZYTybYMu[mG|ZXSgZ4Ft[2Wrbj3BUUBm\m[udYigZZN{[XluIFnDOVA:OC5{MkROwG0> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5MEWxPUc,OTlzN{C1NVk9N2F-
Kb-V1 MXnGeY5kfGmxbjDhd5NigQ>? M{GzVFExKG2rboO= NHzWS5VKdmirYnn0bY9vKG:oIFHCR2IyKGW6cILld5Nm\CCrbjDLZk1XOSClZXzsd{Bi\nSncjCxNEBucW6|IHL5JINidGOnaX6tRW0h[XO|YYmsJGlEPTB;MD6yNlPPxE1? Mn3HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{CyPFIoRjJzNUewNlgzRC:jPh?=
KBV1 MWjGeY5kfGmxbjDhd5NigQ>? NGjiS|kyOCCvaX7z NUnVSIRNUW6qaXLpeIlwdiCxZjDBRmNDOSCrbjDoeY1idiCNQm[xJINmdGy|IHHmeIVzKDFyIH3pcpMh[nliQ3HsZ4Vqdi2DTTDtbYNzd3CuYYTlJIF{e2G7LDDJR|UxRTBwMkKz{txO NWHo[ZVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3QDNpPkK0PVAxPjh|PD;hQi=>
NCI-ADR-RES NIPkdnpHfW6ldHnvckBie3OjeR?= M1nzXVExODBibl2= NXvqTY56PzJiaILz MXrJcohq[mm2aX;uJI9nKGi3bXHuJGFDS0JzIHX4dJJme3OnZDDpckBPS0lvQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCyb4TlcpRq[XSrb36gc4Yh\G:6b4L1ZolkcW5vaX7keYNm\CCleYTveI95cWOrdImgZpkhdWWjc4XybY5oKGSxeH;yeYJq[2mwIFnDOVAh[XRiMUCwNEBvVSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6KCiUdnKgQUA2NjV2IDuvMUAxNjZyIIXNLUwhUUN3ME2wMlI1|ryP M1nXcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUC0OlY6Lz5{N{WwOFY3QTxxYU6=
MCF7/Topo NUjGWWc6TnWwY4Tpc44h[XO|YYm= MYrJcohq[mm2aX;uJI9nKEGEQ1eyJIlvKGi3bXHuJG1ETjdxVH;wc{Bk\WyuczDifUBJd2WlaIP0JFM{OzR{IHHzd4F6NCCLQ{WwQVAvPTMQvF2= NVXrO2xkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3O|QxOzhpPkK2O|c1ODN6PD;hQi=>
MCF7/Topo NVjrdnlGTnWwY4Tpc44h[XO|YYm= NX\5[417UW6qaXLpeIlwdiCxZjDBRmNIOiCneIDy[ZN{\WRiaX6gbJVu[W5iTVPGO{9Vd3CxIHPlcIx{KGK7IFjv[YNpe3RibXnjdo9xdGG2ZTDhd5NigSxiSVO1NF0xNjV{Nt88US=> NGXHSpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NFI5Oid-MkG1O|AzQDJ:L3G+
MCF7/Topo NGTFdJpHfW6ldHnvckBie3OjeR?= M3n1fFIhcHK| NWjxRXFSUW6qaXLpeIlwdiCxZjDBRmNIOiCrbjDoeY1idiCPQ1[3M3RweG9iY3XscJMh[W[2ZYKgNkBpenNiYomgTI9m[2i|dDCzN|M1OiCvaXPyc5Bt[XSnIHHzd4F6NCCLQ{WwQVAvPTJ4zszN NYnMSItmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3QDNpPkK0PVAxPjh|PD;hQi=>
MCF7/Topo NHKx[HNHfW6ldHnvckBie3OjeR?= NIjWXGMzKGi{cx?= NIT5XYxKdmirYnn0bY9vKG:oIFHCR2czKGmwIHj1cYFvKE2FRkevWI9xdyClZXzsd{Bi\nSncjCyJIhzeyCkeTDIc4VkcHO2IEOzN|QzKHO2YXnubY5oKGKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2wMlUzPs7:TR?= NV3ETpdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxNlgxQDBpPkOwNVI5ODhyPD;hQi=>
MCF7 MX MmftSpVv[3Srb36gZZN{[Xl? Ml\FTY5pcWKrdHnvckBw\iCEQ2LQJIV5eHKnc4Pl[EBqdiCPQ1[3JG1ZKGOnbHzzJIJ6KEixZXPod5QhOzN|NEKgd5RicW6rbnesJGlEPTB;MD62PO69VQ>? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl|Mkm2NEc,OTl7M{K5OlA9N2F-
MDCK NGG0VWZHfW6ldHnvckBie3OjeR?= NUPvUIR[UW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CCrbjDNSGNMKGOnbHzzJIJ6KHCqZX;wbI9z[mmmZTDBJIF{e2G7LDDJR|UxRTBwOEZOwG0> NYHvcY1ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5N|I6PjBpPkG5PVMzQTZyPD;hQi=>
MCF7/Topo NFLncY5HfW6ldHnvckBie3OjeR?= NVTPb5lOUW6qaXLpeIlwdiCxZjDBRmNIOiCxdnXy[ZhxemW|c3XkJIlvKGi3bXHuJG1ETjdxVH;wc{Bk\WyuczDifUBndG:5IHP5eI9u\XS{aXOtZoF{\WRibXn0c5hidnS{b37lJIVn\my3eDDhd5NigSxiSVO1NF0xNjlzNt88US=> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5MEWxPUc,OTlzN{C1NVk9N2F-
MDCK M2j5b2Z2dmO2aX;uJIF{e2G7 NWXLXGJKUW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CCrbjDNSGNMKGOnbHzzJJV{cW6pIFjv[YNpe3RiM{OzOFIhe3SjaX7pcoctKEmFNUC9NE46PM7:TR?= NYjsfYU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzOVQ5ODBpPkKxN|U1QDByPD;hQi=>
HFE MmnJR5l1d3SxeHnjbZR6KGG|c3H5 M{K4flczKGi{cx?= MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDISmUh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkK4{txO M1rDTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUm3NVYxLz5{NkG5O|E3ODxxYU6=
MCF7 M3nYXmZ2dmO2aX;uJIF{e2G7 M4THPWlvcGmkaYTpc44hd2ZiQVLDS|IhcW5iaIXtZY4hdWm2b4jhcpRzd26nLYLld4l{fGGwdDDNR2Y4KGOnbHzzJIJ6KEixZXPod5QhOzN|NEKgZZN{[XluIFnDOVA:OS52NEW0OO69VQ>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ5OES5OUc,OTh4N{i0PVU9N2F-
MCF-7 MX MXfGeY5kfGmxbjDhd5NigQ>? NE\ObYhKdmirYnn0bY9vKG:oIFLDVnAh\XiycnXzd4VlKGmwIF3DSk04KE2[IHPlcIx{KHW|aX7nJGhw\WOqc4SgN|M{PDJic4ThbY5qdmduIFnDOVA:OS53zszN M3K1c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{W0PFAxLz5{MUO1OFgxODxxYU6=
K562/A02 MUjGeY5kfGmxbjDhd5NigQ>? M{nYRlQ5KGi{cx?= MVzJcohq[mm2aX;uJI9nKEGEQ1KxJIlvKGi3bXHuJGs2PjJxQUCyJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDh[JJq[W27Y3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzDBSHIhUUN3MDDt[YF{fXKnZDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7IDjSeoIhRSB3MT6zOEAsNy1iNT6xJJVOMSxiSVO1NF0yNjcQvF2= MoLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NEW4N|EoRjJ6NkS1PFMyRC:jPh?=
K562/A02 MlXFSpVv[3Srb36gZZN{[Xl? NUPtOIZvPSC3TR?= MUe0PEBpenN? NFvt[mxKdmirYnn0bY9vKG:oIFHCR2IyKGmwIHj1cYFvKEt3NkKvRVAzKGOnbHzzJIF{e2W|c3XkJIF{KHCxdHXueIlifGmxbjDv[kBi\HKrYX35Z4lvNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHL5JI1m[XO3cnnu[{BCTFJiSVO1NEBifCB3IIXNJI1m[XO3cnXkJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmgLHJ3[iB;IESzMlc2KHSxIEm2MlkyKHWPKTygTWM2OD1zLkm3{txO NV76d49kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OFU5OzFpPkK4OlQ2QDNzPD;hQi=>
K562/A02 NXe3[5dITnWwY4Tpc44h[XO|YYm= NX;zV|l4PDhiaILz M2jWTmlvcGmkaYTpc44hd2ZiQVLDRlEhcW5iaIXtZY4hUzV4Mj;BNFIh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJIFlemmjbYnjbY4ucW6mdXPl[EBkgXSxdH;4bYNqfHliYomgcYVie3W{aX7nJGFFWiCLQ{WwJJRz\WG2ZXSg[o9zKDR6IHjyd{Bnd2yub4fl[EBjgSClb33wc5Vv\CC5YYPoc5V1KG2nYYP1doVlKGmvbXXkbYF1\Wy7IHL5JG1VXCCjc4PhfUApWn[kIE2gOVEvOzRiKz:tJFUvOSC3TTmsJGlEPTB;Mz6wNu69VQ>? M12yWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkS1PFMyLz5{OE[0OVg{OTxxYU6=
KBV MljpSpVv[3Srb36gZZN{[Xl? M3HlPVExKHWP MWC3NkBpenN? M{K5TXJmfmW{c3HsJI9nKFBvZ4CtcYVlcWG2ZXSg[JJ2\yC{ZYPpd5RidmOnIHnuJIh2dWGwIFvCWkBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCkeTDt[YF{fXKrbnegdIFkdGm2YYjlcEBKSzVyIHH0JFExKHWPIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XliKGL2ZkA:KDN7OD6zOEAsNy1iMD61PEB2VSluIFnDOVA:PC52Nt88US=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN6NEC0Nkc,OzB|OESwOFI9N2F-
K562/A02 MlHESpVv[3Srb36gZZN{[Xl? MWq0PEBpenN? M4XRNmlvcGmkaYTpc44hd2ZiQVLDRlEhcW5iaIXtZY4hUzV4Mj;BNFIh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJIFlemmjbYnjbY4ucW6mdXPl[EBkgXSxdH;4bYNqfHliYomgcYVie3W{aX7nJGFFWiCLQ{WwJJRz\WG2ZXSg[o9zKDR6IHjyd{Bnd2yub4fl[EBjgSClb33wc5Vv\CC5YYPoc5V1KG2nYYP1doVlKGGodHXyJFYhcHK|IHL5JG1VXCCjc4PhfUApWn[kIE2gOVEvOzRiKz:tJFUvOSC3TTmsJGlEPTB;ND65O:69VQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ2NUizNUc,Ojh4NEW4N|E9N2F-
KBV MV7GeY5kfGmxbjDhd5NigQ>? M3nFO|UhfU1? MV:3NkBpenN? M3ryNXJmfmW{c3HsJI9nKFBvZ4CtcYVlcWG2ZXSg[JJ2\yC{ZYPpd5RidmOnIHnuJIh2dWGwIFvCWkBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCkeTDt[YF{fXKrbnegdIFkdGm2YYjlcEBKSzVyIHH0JFUhfU1iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSBqUo\iJF0hOzl6LkO0JEswNSByLkW4JJVOMSxiSVO1NF02NjJ2zszN MmjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|OESwOFIoRjNyM{i0NFQzRC:jPh?=
K562/A02 NISwcJNHfW6ldHnvckBie3OjeR?= NY\PcFR4PDhiaILz MULJcohq[mm2aX;uJI9nKEGEQ1KxJIlvKGi3bXHuJGs2PjJxQUCyJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDh[JJq[W27Y3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzDBSHIhUUN3MDD0doVifGWmIH\vdkA1QCCqcoOg[o9tdG:5ZXSgZpkh[2:vcH;1coQhf2G|aH;1eEBu\WG|dYLl[EBi\nSncjCxNkBpenNiYomgUXRVKGG|c3H5JEhTfmJiPTC1NU4{PCBtLz2gOU4yKHWPKTygTWM2OD16LkK4{txO NVzuN|BZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OFU5OzFpPkK4OlQ2QDNzPD;hQi=>
HCT116 NW\LfpNKS3m2b4TvfIlkcXS7IHHzd4F6 NYDsXlF3PDhiaILz NHGyTJFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yOi53zszN NHr0NIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG5O|E3OCd-Mk[xPVcyPjB:L3G+
MCF7/ADR MWfDfZRwfG:6aXPpeJkh[XO|YYm= NUXqc2VkPDhiaILz MUjJcpRzcW6|aXOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPy:DRGKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yOy5zzszN M{fxWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{K4NFI6Lz5{N{OyPFAzQTxxYU6=
CEM/VLB500 NIjJbJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml3ZN{Bl[Xm| MWXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDSW0wXkyENUCwJINmdGy|IHHmeIVzKDNiZHH5d{BjgSC{ZYPhfpVzcW5iYYPzZZktKEeLNUC9NVMvPc7:TR?= M{HpcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{m5PVkxLz5zN{O5PVk6ODxxYU6=
K562/A02 NEDxWYxHfW6ldHnvckBie3OjeR?= NGCzcYM1QCCqcoO= MXTJcohq[mm2aX;uJI9nKEGEQ1KxJIlvKGi3bXHuJGs2PjJxQUCyJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDh[JJq[W27Y3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzDBSHIhUUN3MDD0doVifGWmIH\vdkA1QCCqcoOg[o9tdG:5ZXSgZpkh[2:vcH;1coQhf2G|aH;1eEBu\WG|dYLl[EBi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5JEhTfmJiPTC1NU4{PCBtLz2gOU4yKHWPKTygTWM2OD1zND6zPe69VQ>? NVfFOI1ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2OFU5OzFpPkK4OlQ2QDNzPD;hQi=>
HLF NVXKUmU6S3m2b4TvfIlkcXS7IHHzd4F6 NHG1RZc1QCCqcoO= M3XyPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiORjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE3NjZ7zszN MkTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|MkiwNlkoRjJ5M{K4NFI6RC:jPh?=
SW620 MnflR5l1d3SxeHnjbZR6KGG|c3H5 MWi0PEBpenN? NFfaV|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzZ{MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2|ryP MorIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUexOlAoRjJ4MUm3NVYxRC:jPh?=
SW620/AD300 MUjDfZRwfG:6aXPpeJkh[XO|YYm= M{fYdlQ5KGi{cx?= MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOC:DREOwNEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTJ3zszN MnPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOUexOlAoRjJ4MUm3NVYxRC:jPh?=
CCD-18Co MX3DfZRwfG:6aXPpeJkh[XO|YYm= NF;ReoI1QCCqcoO= MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR2QuOTiFbzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI2|ryP NXLvS5U4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPVcyPjBpPkK2NVk4OTZyPD;hQi=>
K562/A02 M{LkPGN6fG:2b4jpZ4l1gSCjc4PhfS=> NUXKSlN[PDhiaILz M1zrUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJxQUCyJINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFBvZ4CgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NlcvOToQvF2= NGDzVlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[zNVc5Pid-Mkm2N|E4QDZ:L3G+
K562/A02 NIP5dpFEgXSxdH;4bYNqfHliYYPzZZk> MWC0PEBpenN? M4TmPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJxQUCyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OjdwMUpOwG0> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ2NUizNUc,Ojh4NEW4N|E9N2F-
K562 NFXzO3VEgXSxdH;4bYNqfHliYYPzZZk> M2PxNlQ5KGi{cx?= NG\2PJpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTNzLkW2{txO MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ|MUe4Okc,Ojl4M{G3PFY9N2F-
K562 Mn\qR5l1d3SxeHnjbZR6KGG|c3H5 MmHDOFghcHK| MmriR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOxMlU3|ryP MlH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NEW4N|EoRjJ6NkS1PFMyRC:jPh?=
HepG2 NIDKRm9EgXSxdH;4bYNqfHliYYPzZZk> MUi0PEBpenN? MmDmR5l1d3SxeHnjbZR6KGGpYXnud5Qh[WS{aXHtfYNqdi2{ZYPpd5RidnRiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0{Py5{zszN MonoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|MkiwNlkoRjJ5M{K4NFI6RC:jPh?=
KB-V1 NWTkXmxpTnWwY4Tpc44h[XO|YYm= MnHiNlAxKG6P MU\Jcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gT2IuXjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gdohw\GGvaX7lJFEzOyCjY3P1cZVt[XSrb36gZZQhOjByIH7N Mn\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4NUeyO|EoRjJzNkW3NlcyRC:jPh?=
SK-N-MC M4C3Z5FJXFNiYYPzZZk> NETsN3dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NFrrWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH NWfKd|BxeUiWUzDhd5NigQ>? MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MnP2dWhVWyCjc4PhfS=> NWezfnFUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> Mn3RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
K562/DOX MlvLSpVv[3Srb36gZZN{[Xl? NEm4VJcyKHWP M17WdVExKG2rboO= NWrucZhIUW6qaXLpeIlwdiCxZjDQMYdxKGmwIHj1cYFvKEt3NkKvSG9ZKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIILoc4RidWmwZT2xNlMh\W[obIX4JIlvKGi3bXHuJGs2PjJiY3XscJMh[XRiMTD1UUBqdmO3YnH0[YQh\m:{IEGwJI1qdnNiaILzJIJ6KG[ub4egZ5l1d22ndIL5JJJmdGG2aY\lJJRwKHWwdILlZZRm\CClb370do9t MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDFzM{GyPEc,OjhzMUOxNlg9N2F-
A2780adr NHv0bmVHfW6ldHnvckBie3OjeR?= NEjGco4yOCC3TR?= MnnTN|AhdWmwcx?= NVrRZ|ZHUW6qaXLpeIlwdiCxZjDBRmNDOSCrbjDoeY1idiCDMke4NIFleiClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44hd2ZiY3HsZ4VqdiCDTTDheEAyOCC3TTDwdoVqdmO3YnH0[YQh\m:{IEOwJI1qdnNiZn;scI94\WRiYomgZ4Ft[2WrbjDBUUBi\GSrdHnvckBu\WG|dYLl[EBmfmW{eTC2NEB{\WO|IH\vdkA3OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:u NEfNXJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0O|I4Oid-Mkm1OFczPzJ:L3G+
HepG2 M1HzTWZ2dmO2aX;uJIF{e2G7 NEjFfZcyOCC3TR?= MonBPVAhdWmwcx?= NFf6bolKdmirYnn0bY9vKG:oIGCt[5AhdWWmaXH0[YQh\W[obIX4JIlvKGGmcnnhcZlkcW5vcnXzbZN1[W62IHj1cYFvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJIlvfHKjY3XscJVt[XJicnjv[IFucW6nLUGyN{Bi[2O3bYXsZZRqd25iYYSgNVAhfU1iaX7jeYJifGWmIHnuJIRiemtiY3;u[Il1cW:wIH\vdkA6OCCvaX7zJIJ6KG[ub4egZ5l1d22ndIL5JJJmdGG2aY\lJJRwKGOxboTyc4w> MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN{OECyPUc,Ojd|MkiwNlk9N2F-
Assay
Methods Test Index PMID
Immunofluorescence MRP7 23393594
In vivo Tariquidar (2- 8 mg/kg p.o.) is found to significantly potentiate the antitumor activity of doxorubicin (5 mg/kg, i.v.) against MC26 murine colon carcinoma in vivo. In human carcinoma xenografts, coadministration of XR9576 (6 -12 mg/kg p.o.) fully restored the antitumor activity of paclitaxel, etoposide, and vincristine against two highly resistant MDR human tumor xenografts (2780AD, H69/LX4) in nude mice. [3]

Protocol (from reference)

Kinase Assay:

[1]

  • Steady-state drug accumulation assay:

    AuxB1 and CHrB30 cells are grown to confluency in 12-well (24 mm) tissue culture dishes and the steady-state accumulation of [3H]-vinblastine is measured. Accumulation is initiated by the addition of 0.1 μ Ci [3H]-vinblastine and unlabelled vinblastine to a final concentration of 100 nM . The accumulation of [3H]-paclitaxel is measured using 0.1 μ Ci [3H]-paclitaxel and unlabelled drug to a final concentration of 1 μM . Cells are incubated in a reaction volume of 1 mL for 60 min at 37 ℃ under 5% CO2 in order to reach steady-state. The effect of the modulators XR9576 on [3H]-ligand accumulation is investigated in the concentration range 10-9 - 10-6 M. Modulators are added from a DMSO stock giving a final solvent concentration of 0.2 % (v/v). Following cell harvesting, accumulated drug is measured by liquid scintillation counting and normalized for cell protein content. Plots of amount accumulated as a function of modulator concentration are fitted with the general dose-response equation: Y={(a-b)/(1+(X/c)d)}+bWhere: Y=response; a=initial response; b=final response; c=EC50 concentration; d=slope value; X=drug concentration.

Cell Research:

[3]

  • Cell lines: Murine mammary carcinoma cell line MDR EMT6/AR1.0
  • Concentrations: ~100 nM Tariquidar
  • Incubation Time: 4 days
  • Method:

    Cells are seeded into 96-well plates at 800/well, in 100 μL of medium and incubated for 4 h at 37 ℃. Varying concentrations of modulator or solvent control (50 μL/well) are subsequently added and incubated for an additional 1 h before the addition of the cytotoxic drug. The cytotoxic drug (50 μL) is added to give a range of final concentrations in quadruplicate wells. After incubation for an additional 4 days, cell proliferation of adherent cells is assessed using the sulforhodamine B assay.

Animal Research:

[3]

  • Animal Models: Murine colon carcinoma xenografts MC26
  • Dosages: 8 mg/kg
  • Administration: Coadministration of Tariquidar (p.o.) with doxorubicin (5 mg/kg, i.v.)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 646.73
Formula

C38H38N4O6

CAS No. 206873-63-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01663545 Completed -- Epilepsies Partial National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) July 31 2012 --
NCT01547754 Terminated -- HIV-Associated Cognitive Motor Complex National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) January 9 2012 --
NCT01386476 Completed -- Drug Resistance National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC) June 15 2011 --
NCT00082368 Completed Drug: Tariquidar|Drug: Tc-94m Sestamibi Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 16 2004 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Can you please give me more specific and detailed information of how to dissolve and use this compound (S8028) for in vivo studies?

Answer:
Tariquidar in 30% Propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml will be a suspension or emulsion. If you are going to administrate the compound by oral gavage, it is fine. We also have test some vehicles for Tariquidar for i.p injection, and it is soluble in 5% DMSO+45% PEG 300+ddH2O at 2mg/ml clearly. When preparing the solution, please dissolve the compound in DMSO clearly first, then add PEG. After they mixed well, then dilute with water.

Tags: buy Tariquidar (XR9576) | Tariquidar (XR9576) supplier | purchase Tariquidar (XR9576) | Tariquidar (XR9576) cost | Tariquidar (XR9576) manufacturer | order Tariquidar (XR9576) | Tariquidar (XR9576) distributor